Physician profile
Gregory A Sharp
NPI 1639179898
$18,656.61
in general payments reported to CMS, 2019-2025
37 companies · $3,825 in 2025
The $3,825 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,333 · 2022: $3,763 · 2023: $4,419 · 2024: $4,316 · 2025: $3,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,977.58 |
| Education | $582.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,632.79 | 2021-2025 | |
| Ucb, INC. | $1,810.60 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,784.13 | 2021-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,758.43 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,479.47 | 2021-2025 | Ilumya, Blu-U, Winlevi |
| Incyte Corporation | $1,190.93 | 2021-2025 | Opzelura |
| Genzyme Corporation | $768.75 | 2021-2025 | |
| Leo Pharma INC. | $753.76 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $742.48 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $716.38 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $707.13 | 2022-2024 | Vtama |
| Lilly USA, LLC | $651.58 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $539.24 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $289.45 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $265.65 | 2023-2025 | Zoryve |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $236.99 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.81 | 2021-2024 | Cabtreo, Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.07 | 2022-2025 | Spevigo, Cyltezo |
| Amgen INC. | $157.70 | 2022-2025 | Otezla, Otezla |
| Almirall LLC | $129.04 | 2021-2025 | Seysara, Klisyri |
| Galderma Laboratories, L.P. | $111.62 | 2021-2025 | Nemluvio |
| Organon LLC | $100.98 | 2023-2025 | Vtama, Hadlima |
| Journey Medical Corporation | $82.64 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $74.37 | 2023-2024 | Idacio |
| Kerecis Limited | $59.55 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Botanix Sb INC | $28.92 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $27.47 | 2022 | |
| Organogenesis INC. | $27.39 | 2024 | Cygnus Dual |
| Epi Health, LLC | $27.28 | 2021-2022 | |
| Hill Dermaceuticals, INC. | $25.80 | 2023 | Tolak |
| Nabriva Therapeutics, Plc | $23.52 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.08 | 2025 | Acthar |
| Verrica Pharmaceuticals INC. | $20.22 | 2024 | Ycanth |
| Biofrontera INC. | $17.49 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.63 | 2022 | |
| Bioventus LLC | $14.09 | 2022 | |
| Dermira, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.